Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI351 and Cetuximab in KRAS G12C Mutated Metastatic Colorectal Cancer
NCT05497336Phase 1Terminated
- Sponsor
- Innovent Biologics
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fulzerasib in colorectal cancer (CRC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Dose-limiting Toxicity at 28 days and Objective Response Rate at 1 year. Started Aug 2022; status: terminated.
02
Drugs
fulzerasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05497336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497336.